|Bid||12.92 x 800|
|Ask||13.44 x 800|
|Day's Range||13.01 - 13.46|
|52 Week Range||8.36 - 27.00|
|Beta (3Y Monthly)||4.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.25|
IgA nephropathy is a kidney disease resulting from the accumulation of an antibody called immunoglobin A in the kidney, which causes inflammation and in turn impacts the ability of the kidney to filter wastes from blood. Following a meeting with the FDA on the Phase 3 trial, Omeros said Thursday it has finalized its clinical plan for OMS721. The company said the FDA agreed to extend the primary endpoint of the assessment of proteinuria from 24 weeks to 36 weeks to allow additional dosing if warranted.
Omeros Corporation (OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. There is no approved treatment for IgA nephropathy.
Omeros Corporation (OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018. Omeros’ preliminary (unaudited) total and OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% revenues for the fourth quarter of 2018 are expected to be a record high at approximately $22.0 million compared to $4.6 million in 3Q 2018 and $13.8 million in the prior year fourth quarter. The increase from the prior periods reflects strong demand for OMIDRIA from ambulatory surgery centers (ASCs) and hospitals following reinstatement of pass-through reimbursement for OMIDRIA on October 1, 2018.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Omeros Corporation (OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy. The committee includes renowned leaders in nephrology and clinical research who will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
Omeros Corporation (OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –
Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
Omeros Corporation (OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Omeros has granted the initial purchasers of the Notes an option to purchase up to an additional $40 million aggregate principal amount of the Notes on the same terms and conditions referenced above. The Notes will be senior unsecured obligations of Omeros and interest will be payable semi-annually in arrears at a rate of 6.25% per annum.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Seattle-based company said it had a loss of 81 cents. Losses, adjusted for non-recurring costs, were 71 cents per share. The drug developer posted revenue of $4.6 million in the ...
SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Securities Act"). Omeros also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $40 million aggregate principal amount of the Notes, for a total potential offering size of $250 million. The Notes will mature on November 15, 2023, unless earlier converted, repurchased or redeemed in accordance with their terms, and will be convertible, subject to the satisfaction of certain conditions, into cash, shares of Omeros' common stock or a combination thereof as elected by Omeros in its sole discretion.
Omeros Corporation (OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. In addition, Omeros has a diverse group of preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development.
Omeros Corporation (OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.